AELMHU launches an expert panel to reflect on the criteria for funding orphan drugs

"The Spanish Association of Orphan and Ultra-Orphan Drug Laboratories (AELMHU) has launched the first phase of the multi-criteria and multi-decisional decision analysis project on the financing of orphan drugs for rare diseases in Spain.

The expert group was attended by representatives of the health administration, patients, clinicians, hospital pharmacists and health economists.

The aim of this meeting was to review the criteria documented worldwide on the financing of orphan drugs and to establish a debate to analyse and specify those that best define the differentiating characteristics of these drugs in Spain. Thus, the discussion of this phase of the project, coordinated by Pharmacoeconomics & Outcomes Research Iberia (PORIB), revolved around four main categories: target population, disease, treatments and economic evaluation".